Abiraterone (Zytiga, Yonsa)
Other Medications · Approved since 2011
Description
Abiraterone acetate is an androgen biosynthesis inhibitor primarily approved for metastatic castration-resistant prostate cancer treatment. In colorectal cancer, abiraterone is used off-label in select cases, particularly in research settings exploring hormone pathway involvement in CRC progression. The drug's inclusion in solid tumor trials suggests potential activity beyond its established prostate cancer indication.
Mechanism of Action
Abiraterone irreversibly inhibits CYP17A1 (17 -hydroxylase/C17,20-lyase), a key enzyme in androgen biosynthesis that converts pregnenolone and progesterone to their 17 -hydroxy derivatives and subsequently to dehydroepiandrosterone (DHEA) and androstenedione. By blocking this enzyme, abiraterone depletes circulating and intratumoral androgens, potentially disrupting androgen receptor signaling pathways that may contribute to tumor growth in certain solid tumors including colorectal cancer.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Zytiga, Yonsa |
| Category | Other Medications |
 Status | Off-label |
 EMA Status | EMA Approved |
 Spain Access | Funded by SNS off-label in CRC |
| Administration | Oral |
| Year Approved | 2011 |
| Clinical Trials | 2 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.